Lipid CME

This activity is expired and is no longer available for CME credit.


Cardiovascular Risk Reduction With PCSK9 Inhibitors: Evolving Evidence, Recommendations, and Controversies

Author(s)/Faculty: Michael H. Davidson, MD, FACC, FACP, FNLA; Christie M. Ballantyne, MD; Elizabeth Jackson, MSN, ACNS-BC, CLS, FNLA
Release Date: 7/16/2019Expiration Date: 7/15/2020
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have proven to be safe and efficacious in both current and ongoing clinical trials. Their use in patients has demonstrated significantly lowered low-density lipoprotein levels and a reduction in major adverse cardiovascular events. However, many clinicians still do not use these medications in their daily practice. Physicians, pharmacists, and nurses need to be aware of the latest clinical evidence regarding PCSK9 inhibitors and how to overcome the barriers associated with obtaining these drugs for their patients. In this educational activity, expert clinicians will discuss the efficacy and safety of PCSK9 inhibitors as well as provide guidance regarding when to prescribe these medications and how to obtain them for their patients. In addition, participants will engage in Game On! – an interactive, confidence-based activity.